Leerink Swann began coverage on shares of Epizyme (NASDAQ:EPZM) in a report released on Monday, The Fly reports. The brokerage set a “market perform” rating on the biopharmaceutical company’s stock.

EPZM has been the topic of a number of other research reports. BidaskClub downgraded Epizyme from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Epizyme in a research report on Wednesday, June 27th. Zacks Investment Research downgraded Epizyme from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Morgan Stanley set a $12.00 price target on Epizyme and gave the stock a “hold” rating in a research report on Friday, September 7th. Finally, ValuEngine downgraded Epizyme from a “hold” rating to a “sell” rating in a research report on Thursday, June 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. Epizyme currently has a consensus rating of “Hold” and an average price target of $21.73.

Shares of EPZM traded down $0.05 during mid-day trading on Monday, reaching $10.25. The company had a trading volume of 1,295,154 shares, compared to its average volume of 450,269. Epizyme has a 52-week low of $8.61 and a 52-week high of $21.40. The company has a market capitalization of $712.41 million, a price-to-earnings ratio of -4.70 and a beta of 1.82.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The company had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $0.54 million. The firm’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.48) EPS. equities research analysts expect that Epizyme will post -2.13 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its position in shares of Epizyme by 0.6% in the first quarter. Northern Trust Corp now owns 580,898 shares of the biopharmaceutical company’s stock valued at $10,311,000 after acquiring an additional 3,538 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Epizyme by 9.4% in the first quarter. Rhumbline Advisers now owns 48,210 shares of the biopharmaceutical company’s stock valued at $856,000 after acquiring an additional 4,130 shares in the last quarter. BB&T Securities LLC lifted its position in shares of Epizyme by 45.5% in the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 5,000 shares in the last quarter. New York State Common Retirement Fund lifted its position in shares of Epizyme by 11.8% in the first quarter. New York State Common Retirement Fund now owns 52,100 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Epizyme by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 225,764 shares of the biopharmaceutical company’s stock valued at $3,058,000 after acquiring an additional 6,012 shares in the last quarter. Institutional investors and hedge funds own 85.06% of the company’s stock.

Epizyme Company Profile

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Featured Story: New Google Finance Tool and Screening Stocks

The Fly

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.